255 related articles for article (PubMed ID: 35579824)
1. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
[TBL] [Abstract][Full Text] [Related]
2. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression.
Perez-Ruixo C; Rossenu S; Zannikos P; Nandy P; Singh J; Drevets WC; Perez-Ruixo JJ
Clin Pharmacokinet; 2021 Apr; 60(4):501-516. PubMed ID: 33128208
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
6. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
7. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
9. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.
Frechen S; Solodenko J; Wendl T; Dallmann A; Ince I; Lehr T; Lippert J; Burghaus R
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):633-644. PubMed ID: 33946131
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
[TBL] [Abstract][Full Text] [Related]
11. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
13. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
14. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
Min JS; Bae SK
Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
[TBL] [Abstract][Full Text] [Related]
15. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
16. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
Kollipara S; Ahmed T; Praveen S
Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data From a Japanese Phase 2b Study.
Kurosawa K; Shibuya M; Shimizu H; Pérez-Ruixo C
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):397-406. PubMed ID: 36560916
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]